|1||Active, not recruiting||
CRLX101 Plus Bevacizumab in Advanced RCC
A Phase 2 Study of CRLX101 in Patients With Advanced Non-Small Cell Lung Cancer
Alternative Dosing for CRLX101 Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
|4||Active, not recruiting||
CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
|5||Active, not recruiting||
A Study of CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
|6||Active, not recruiting||
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
Efficacy Study of Maintenance Therapy for Ovarian Cancer Patients
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors
|10||Active, not recruiting||
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
† Study has passed its completion date and status has not been verified in more than two years.